Fibrillarin (FBL) (NM_001436) Human Tagged ORF Clone Lentiviral Particle

SKU RC200732L1V

Lenti ORF particles, FBL (Myc-DDK tagged) - Human fibrillarin (FBL), 200ul, >10^7 TU/mL

Product Data

• Type: Human Tagged ORF Clone Lentiviral Particle
• Tag: Myc-DDK
• Target Symbol: Fibrillarin
• Synonyms: FIB; FLRN; Nop1; RNU3IP1
• Vector: pLenti-C-Myc-DDK
• Mammalian Cell Selection: None
• Sequence Data:
  ORF Nucleotide Sequence

  The ORF insert of this clone is exactly the same as(RC200732).
• ACCN: NM_001436
• ORF Size: 963 bp
• OTI Disclaimer: The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
• OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
• Shipping: Dry Ice

Reference Data

• RefSeq: NM_001436.2
• RefSeq Size: 1135 bp
• RefSeq ORF: 966 bp
• Locus ID: 2091
• UniProt ID: P22087
• Cytogenetics: 19q13.2
• Domains: Fibrillarin
• Protein Families: Stem cell - Pluripotency
• MW: 33.6 kDa
• Summary: This gene product is a component of a nucleolar small nuclear ribonucleoprotein (snRNP) particle thought to participate in the first step in processing preribosomal RNA. It is associated with the U3, U8, and U13 small nuclear RNAs and is located in the dense fibrillar component (DFC) of the nucleolus. The encoded protein contains an N-terminal repetitive domain that is rich in glycine and arginine residues, like fibrillarins in other species. Its central region resembles an RNA-binding domain and contains an RNP consensus sequence. Antisera from approximately 8% of humans with the autoimmune disease scleroderma recognize fibrillarin. [provided by RefSeq, Jul 2008]